Nachrichten zur Neurocrine Biosciences Aktie

Neurocrine Biosciences Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine…

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

SAN DIEGO, May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug…

Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 1.144.463$

Pops, Richard F. - Aufsichtsrat - Tag der Transaktion: 2022-05-09...…

Neurocrine Biosciences (NBIX) Q1 2022 Earnings Call Transcript

NBIX earnings call for the period ending March 31, 2022....…

Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the…

Neurocrine Biosciences Inc Q1 Profit Decreases, misses estimates

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that decreased from last year and missed…

Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

INGREZZA® (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA® (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25…

Form 8-K NEUROCRINE BIOSCIENCES For: May 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference

SAN DIEGO, May 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities…

Neurocrine Biosciences Q1 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week

States Across the Country Declare First Week of May (1-7) Tardive Dyskinesia Awareness Week to Raise Awareness of This Burdensome…

Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 1.391.393$

Lyons, Gary A. - Aufsichtsrat - Tag der Transaktion: 2022-04-25...…

Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET

Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022…

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO, April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:…

Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 1.018.366$

Rastetter, William H. - Aufsichtsrat - Tag der Transaktion: 2022-04-01...…

What 8 Analyst Ratings Have To Say About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Latest Ratings for NBIX …

Neurocrine Biosciences Reports Positive Data Of Valbenazine For Chorea In Huntington Disease

WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) announced results from the phase 3 KINECT-HD study, which showed once-daily administration of…

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022

- Valbenazine Met the Primary Endpoint of Significant (p...…

Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan

SAN DIEGO, March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe…

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022

SAN DIEGO, March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data…

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth…